June 25, 2021


U.S. Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549


Attn: Kasey Robinson
  Christopher Edwards


Re: Aerovate Therapeutics, Inc.
  Acceleration Request for Registration Statement on Form S-1
  File No. 333-256949


  Requested Date: June 29, 2021
  Requested Time: 4:30 p.m. Eastern Standard Time


Dear Ms. Robinson and Mr. Edwards:


In accordance with Rule 461 under the Securities Act of 1933, as amended (the “Act”), Jefferies LLC, Cowen and Company, LLC and Evercore Group L.L.C., as representatives of the several underwriters, hereby join Aerovate Therapeutics, Inc. in requesting that the effective date of the above-referenced registration statement (the “Registration Statement”) be accelerated to June 29, 2021, at 4:30 p.m., Eastern Time, or as soon thereafter as practicable.


Pursuant to Rule 460 under the Act, please be advised that we will take reasonable steps to secure adequate distribution of the preliminary prospectus, to underwriters, dealers, institutions and others, prior to the requested effective time of the Registration Statement.


We have been informed by the participating underwriters that they will comply with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended, to the extent applicable.


[Signature Page Follows]





Very truly yours,


As representatives of the several underwriters




By: /s/ Matthew Kim  
  Name:Matthew Kim  
  Title:Managing Director, Joint Head of US Biotechnology  




By: /s/ Bill Follis  
  Name:Bill Follis  
  Title:Managing Director  




By: /s/ Maren Winnick  
  Name:Maren Winnick  
  Title:Senior Managing Director, Advisory